



1631

Attorney Docket No. LSB.0191.NPUS01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	TUSE)	
SERIAL NO.:	10/098,606)	EXAMINER: MAHATAN, C.
FILED:	MARCH 15, 2002)	ART UNIT: 1631
TITLE:	EPISOMAL NON-TRANSFORMING NUCLEIC ACID ELEMENTS IN FUNCTIONAL GENOMIC AND ANTIGENIC APPLICATIONS)	CONF.NO.: 7669

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

An Office Action was mailed in the above-captioned application on February 9, 2004. In such Office Action claims 1-33 were pending. Claims 1-33 were subject to restriction and/or election requirement. This Response to Restriction Requirement document is submitted in response to said Office Action.

ELECTION

Restriction Requirement under 35 U.S.C. § 121

An election requirement was made to pending claims 1-33. The claims were placed into three groups:

Group I (claim 1) drawn to a method of compiling a functional gene profile of a donor organism;

Group II (claim 2) drawn to a method of identifying the sequence of an antigen of a pathogen; and

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 3/9/04

Signature: Tasha L. Cove

Name: Tasha L. Cove


Group III (claims 3-33) drawn to a method of identifying the sequence of an antigen of a cancer cell.

Applicant hereby elects to prosecute the invention of Group III, claims 3-33, without traverse.

It is believed that no fees are due with this submission; however, the undersigned hereby authorizes the charge of any fees created by the filing of this document to be charged to deposit account No. 19-5117.

Respectfully submitted,

Date: March 9, 2004



Darla G. Yoerg, #48,053
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065